Latest News and Press Releases

Study at International Alzheimer's Conference Finds Brain Training Reduces Amyloid

Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a...

Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that...

Vaccinex reports new biomarker research and plans for Phase 2 randomized clinical trial of pepinemab in Alzheimer's Disease at the AAIC in July

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions...

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Dublin, June 25, 2026 (GLOBE NEWSWIRE) -- The "AI in Neurology Market Size, Share & Trends Analysis Report by Application, Neurological Condition, Components, End Use, Region, and Growth...

Oral first-in-class neuroprotective small molecule ALT0135 moves into IND-enabling studies targeting early toxic triggers in Alzheimer’s disease.

Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New...